Anti-angiogenesis therapy:Concepts and importance of dosing schedules in clinical trials

Drug Resistance Updates

Volumn 3, Issue 4, 2000, Pages 223-235

  Mross, Klaus ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Angiogenesis inhibition; Cancer therapy; Metronomic dosing

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CHELATING AGENT; COPPER DERIVATIVE; PROTEINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER RESEARCH; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW;

EID: 0033826472     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0150     Document Type: Article

References (114)

1. Tumor angiogenesis: Therapeutic implications
2. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics
3. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
4. Pituitary follicular cells secrete a novel heparin-binding grwoth factor specific for vascular endothelial cells
5. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells
6. Vascular endothelial growth factors and receptors
7. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF
8. Nucleotide sequence of a bovine clone encoding the angiogenic protein basic fibroblast growth factor
9. Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation
10. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms
11. Bcl-2 family: Regulators of cell death
12. Bcl-2 family proteins
13. Inhibition of cell signalling pathways
14. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma
15. Sequential development of an angiogeneic phenotype by human fibroblasts prgressing to tumorgenicity
16. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane
17. Prolonged dormancy by prevention of neovascularization in the vitreous
18. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
19. A model system for measuring comparative toxicities of cardiotoxic drugs for cultures rat heart myocytes, endothelial cells and fibroblasts. II doxorubicin, 5-Fluoruracil and cyclophosphamide
20. Morphometric study of myocardial changes during doxorubicin induced cardiomyopathy in mice
21. A prospective randomized comparison of continuous infusion fluoruracil with a conventional bolus schedule in metastatic colorectal cancer
22. Phase II study of continuous infusion 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: An active new regimen
23. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
24. Oral trofosfamide: An active drug in the treatment of advanced cancer
25. Tumor growth control by oral trofosfamide in patients with metastatic breast cancer
26. Two oral trofosfamide schedules in elderly patients with refractory non-Hodgkin's lymphoma
27. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models
28. Antiangiogenesis is produced by nontoxic doses of vinblastin
29. Continuous low-dose therapy with vinblastin and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
30. Antiangiogenesis scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
31. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-II studied in the mouse cornea model
32. 5-Fluorouracil: Synchronous application of continuous and bolus therapy in heavily pretreated metastatic colorectal cancer: A phase I/II study
33. Angiogenic factors are hematopoietic growth factors and vice versa
34. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
35. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
36. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow derived endothelial cells
37. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
38. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: A case report
39. Evidence for circulating bone marrow-derived endothelial cells
40. AC133, a novel marker for human hematopoietic stem and progenitor cells
41. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy
42. Antiangiogenic tumour therapy Will it work?
43. Inhibition of malignant angiogenesis
44. Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors
45. Clinical application of research on angiogenesis
46. Tumor angiogenesis: The pivotel role of vascular endothelial growth factor
47. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
48. Tumor angiogenesis A new significant and independent prognostic indicator in early-stage breast carcinoma
49. Association of angiogenesis in lymph node metastases with outcome of breast cancer
50. Vascular grading of angiogenesis: Prognostic significance in breast cancer
51. Angiogenesis in breast cancer: A comparative study of the observer variability of methods for determining microvessel density
52. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: Effects of VEGF-toxin conjugate on tumor microvessel density
53. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
54. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
55. Plasma vascular endothelial but not fibroblast growth factor correlate with colorectal liver metastasis vascularity and volume
56. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impaires vascular endothelial growth factor-induced responses and tumor growth after oral administration
57. Phase I dose escalation, pharmacokinetic (PK) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK222584 (PTK/ZK)
58. Effects of PTK787/ZK222584, a specific inhibitor of vegf-receptor tyrosine kinases, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma
59. Thalidomide in oncology: The peril and the promise
60. Suramin, an anticancer and angiosuppressive agent, inhibits cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator
61. Angiogenesis inhibition: Drugs in clinical trials
62. Inhibitors of angiogenesis enter phase III testing
63. Angiogenesis antagonists: Current clinical trials
64. Tumour angiogenesis: A new target for cancer therapy
65. Growth factors in angiogenesis: Current interest and therapeutic potential
66. Matrix metalloproteinases: Biological activity and clinical implications
67. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
68. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
69. AE-941, an inhibitor of angiogenesis
70. Synthetic analogues of fumagillin that inhibits angiogenesis and suppress tumor growth
71. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix
72. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cancer
73. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470
74. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
75. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
76. Antitumor activity of thalidomide in refractory multiple myeloma
77. Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease
78. A safety, tolerance and pharmacokinetic study of rising dose, rising duration continuous infusion of MSI-1256F (squalamine lactate) in patients with advanced cancer
79. A phase I and pharmacokinetic (PK) study of the antiangiogenesis inhibitor, squalamine lactate (MSI-1256F)
80. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
81. A phase I pharmacokinetic (PK) study of single dose intravenous (iv) combretastatin A4 prodrug (CA4P) in patients with advanced cancer
82. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
83. Angiostatin induces and sustains dormancy of human primary tumors in mice
84. Antiangiogenenic therapy of experimental cancer does not induce acquired drug resistance
85. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
86. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrinbinding motif R.G.D.
87. Multiple forms of angiostatin induce apoptosis in endothelial cells
88. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor (FIk-I/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
89. Clinical strategy for the development of angiogenesis inhibitors
90. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies
91. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
92. Phase I dose-escalating trial of oral SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies
93. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients with metastatic vancer
94. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and longterm safety data
95. Interferon Alpha-2a therapy for life-threatening hemangiomas of infancy
96. Phase II study with interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma
97. Establishing a link between oncogenes and tumor angiogenesis
98. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
99. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
100. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3
101. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor survival
102. Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis
103. Detection of tumor angiogenesis in vivo ba alphaVbeta3-targeted magnetic resonance imaging
104. Phase I study of vitaxin, an anti-angiogenic humanized monoclonal antibody to vascular integrin αvβ3
105. 5 integrin inhibitor
106. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
107. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations
108. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
109. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study
110. Copper stimulates proliferation o human endothelial cells under culture
111. Cancer risk in relation to serum copper levels
112. Regulation of angiogenesis by copper reduction and penicillamine: Antagonism of cytokine and growth factor activity
113. Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from human bone marrow